INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Alec G. Trub1, John E. Bisi1, Catherine Dietrich2, Michael Taylor, Jay C. Strum1, Shom Goel2, Patrick J. Roberts1
1Incyclix Bio, Durham, NC, United States, 2The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia